Novartis Looks To Bring First-In-Class Vascular Disrupting Agent To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will move the oncologic into Phase III in non-small cell lung cancer in 2008 under a deal with Antisoma, potentially worth more than $890 million.
You may also be interested in...
Novartis/Antisoma's ASA404 Stumbles Badly In Phase III Lung Cancer Trial
Novartis and Antisoma prematurely halted a Phase III study of ASA404 - a potentially first-in-class tumor vascular-disrupting agent - after an interim analysis showed that continuing the trial would be futile. Though lung cancer is a notorious mine field for drug development, the March 29 news still was a big surprise since a similar Phase II trial showed a significant survival benefit in patients treated with the drug
Novartis/Antisoma's ASA404 Stumbles Badly In Phase III Lung Cancer Trial
Novartis and Antisoma prematurely halted a Phase III study of ASA404 - a potentially first-in-class tumor vascular-disrupting agent - after an interim analysis showed that continuing the trial would be futile. Though lung cancer is a notorious mine field for drug development, the March 29 news still was a big surprise since a similar Phase II trial showed a significant survival benefit in patients treated with the drug
Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial
Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.